Ask AI
See Activity Collection
ProCE Banner Activity

TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies

Podcast

In this podcast, experts discuss the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in NSCLC, highlighting current clinical applications, emerging efficacy and safety data, and future treatment strategies. The discussion reviews evidence supporting the use of datopotamab deruxtecan (Dato-DXd) in previously treated EGFR-mutated NSCLC and considerations for treatment selection and sequencing. Emerging data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and findings from ongoing trials evaluating ADC combinations with immunotherapy, chemotherapy, and EGFR-targeted therapies are explored. The experts also address the potential role of the TROP2 QCS-NMR biomarker in identifying patients most likely to benefit from treatment, challenges in interpreting clinical trial outcomes, and practical strategies for preventing and managing adverse events, including stomatitis, ocular toxicity, and interstitial lung disease/pneumonitis. These considerations provide context for integrating TROP2 ADCs into clinical practice as evidence continues to evolve.

Released: October 29, 2026

Begin Activity

Share

Faculty

Christine M. Bestvina

Christine M. Bestvina, MD

Associate Professor of Medicine
Section of Hematology/Oncology
Division of Medicine
University of Chicago Medicine
Chicago, Illinois
Joshua E. Reuss

Joshua E. Reuss, MD

Thoracic Medical Oncologist
Director of Thoracic Clinical Research
Associate Professor of Medicine
Georgetown Lombardi Comprehensive Cancer Center
Washington, DC

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck Sharp & Dohme LLC.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Target Audience

This activity is intended for medical oncologists, pulmonologists, and other healthcare professionals involved in the care of patients with advanced/metastatic NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the current and evolving role of TROP2-directed ADCs in advanced/metastatic NSCLC, including current evidence-based use of Dato-DXd and emerging investigational strategies across frontline, biomarker-enriched, and combination settings

  • Apply established biomarkers and patient-specific clinical factors to guide selection, sequencing, and clinical trial referral for TROP2-directed ADCs and ADC-based strategies in advanced/metastatic NSCLC

  • Appraise emerging global clinical trial evidence for TROP2-directed ADCs, including Dato-DXd, sac-TMT/MK-2870, ADC–immunotherapy combinations, ADC–EGFR TKI combinations, and biomarker-driven approaches

  • Implement multidisciplinary strategies to prevent, monitor, and manage TROP2 ADC–associated adverse events, including stomatitis/oral mucositis, ocular toxicity, nausea, myelosuppression, and ILD/pneumonitis

Financial Disclosures

Primary Author

Christine M. Bestvina, MD: advisor/consultant: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, EMD Serono, Exelixis, Genentech, Jazz, Johnson & Johnson, Lilly, MBrace, Merck, Novartis, Pfizer, Rigel, Summit, Turning Point Therapeutics, Voronoi; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb.

Joshua E. Reuss, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, EMD Serono, Gilead, Guardant, Janssen, Lilly, Merck, Natera, Nuvation Bio, Pfizer, Regeneron, Roche Diagnostics, Summit; researcher (paid to institution): Amgen, Arcus, Duality Bio, Genentech/Roche, Genmab, Nuvalent, Onco-C4, Regeneron, Revolution Medicines, Sutro, Verastem.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and generating transcripts from audio/video files. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.